New ASH25 Insights on Bleeding Risk in Cancer-Associated VTE
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”New Insights on Bleeding Risk During Extended Anticoagulation in Cancer-Associated VTE
Presented at ASH25 and published in Lancet Haematology, this post-hoc analysis of the API-CAT trial, led by Prof. Isabelle Mahé, identifies key predictors of clinically relevant bleeding during extended apixaban therapy in patients with active cancer.
Key Predictors of Higher Bleeding Risk
• Anemia and/or thrombocytopenia (HR 1.93)
• Age ≥75 years (HR 1.51)
• Index pulmonary embolism (HR 1.47)
• Male sex (HR 1.38)
These predictors were consistent across cancer types and also aligned with predictors of major bleeding. See manuscript here.”
Title: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Prof Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Prof Charles-Marc Samama, Hélène Helfer, Prof Grigoris Gerotziafas, Prof Silvy Laporte, Prof Eric Vicaut, Prof Patrick Mismetti
Stay updated with Hemostasis Today.
-
Dec 11, 2025, 15:20Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
-
Dec 11, 2025, 15:05Kristof Vercruysse on ”First in Human” Presented at ASH25
-
Dec 11, 2025, 13:59Jeff Schaffnit Shares Sanofi’s Patient Advocacy Voices Series with Caroline Kruse
-
Dec 11, 2025, 12:50Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
-
Dec 11, 2025, 12:34Riitta Lassila on LMWH Benefits in COVID19
-
Dec 11, 2025, 12:30A Neutrophil-Mesangial Cell Axis Promotes Glomerular Injury in Lupus Nephritis
-
Dec 11, 2025, 12:27Roula Farah: Discussing Rare Bleeding Disorders in Abu Dhabi
-
Dec 11, 2025, 12:21Amirali Ebrahimpour: Escherichia coli–Related DIC Case Report
-
Dec 11, 2025, 12:12Zoey Becker: CSL Proves Efficacy of Hemophilia B Gene Therapy Hemgenix Holds up After 5 Years